hepacaf 5000 ui sol. perf. (pdr. + solv.) i.v.
centrale afdeling voor fractionering - departement central de fractionnement s.p.r.l.-b.v.b.a. - immunoglobuline humaine anti-hépatite b 5000 ui/100 ml - poudre et solvant pour solution pour perfusion - 5000 iu - immunoglobuline humaine anti-hépatite b 5000 ui - hepatitis b immunoglobulin
pegasys
pharmaand gmbh - peginterféron alfa-2a - hepatitis c, chronic; hepatitis b, chronic - les immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 et 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. À l'égard de la décision d'initier le traitement chez les patients pédiatriques (voir la section 4. 2, 4. 4 et 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 et 5. pour le virus de l'hépatite c (vhc) de génotype spécifique de l'activité, voir les sections 4. 2 et 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. lorsque vous décidez de commencer un traitement dans l'enfance, il est important de tenir compte de la croissance inhibition induite par la thérapie de combinaison. la réversibilité de l'inhibition de la croissance est incertain. la décision de traiter doit être faite au cas par cas (voir la section 4.
meningitec suspension
nuron biotech b.v. - oligosaccharide du méningocoque de groupe c; protéine crm-197 de corynébactérium diphtheriae - suspension - 10mcg; 15mcg - oligosaccharide du méningocoque de groupe c 10mcg; protéine crm-197 de corynébactérium diphtheriae 15mcg - vaccines
hyperhep b s/d solution
grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums
hyperhep b s/d solution
grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums
hyperhep b s/d solution
grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antiviraux à usage systémique - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
hyperhep b solution
grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums
hyperhep b solution
grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums
prehevbri
vbi vaccines b.v. - antigène de surface de l'hépatite b - hépatite b - vaccins - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.